Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Sarcoidosis-Associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.

NCT03942211 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT03942211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03942211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Sarcoidosis-Associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.
Lead sponsor
Actelion
Phase
Phase 2
Overall status
Terminated
Start date
February 26, 2021
Completion date
April 19, 2023
Enrollment
10 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoidosis-associated pulmonary hypertension